Traws Pharma Reports Third Quarter 2026 Financial Results and Provides Business Highlights
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Traws Pharma (NASDAQ: TRAW) reported a narrower third-quarter net loss alongside final ratutrelvir trial results and progress on tivoxavir marboxil. Net loss was $3.547 million, versus $3.962 million a year earlier; basic and diluted loss per common share narrowed to $0.18 from $0.34. Cash fell to $2.338 million at September 30, 2026, from $3.820 million at year-end.
The 92-subject ratutrelvir Phase 2a study showed median sustained symptom resolution of 13.5 days versus 14.5 days with PAXLOVID in eligible subjects. Traws plans FDA discussions on a registration strategy for PAXLOVID-ineligible patients and expects a fourth-quarter 2026 TXM toxicology resubmission following tablet bridging and retesting. An October 23 agreement permits up to $50 million in common-stock sales to Roth Principal Investments; none have occurred. Nine-month results shifted to a $14.864 million loss from $16.613 million income.
How this balance works
Rhea-AI gives every point it takes from this document a weight. Minor counts 1, Moderate 3 and Major 9, so one Major point outweighs several Minor ones. The bar adds up the weights on each side, and when neither side holds more than 65% of the total the balance reads Mixed.
It reads the document as published, with the same rules for every company, and it does not look at what the market expected or at how the stock traded, so a point can be objectively good on a day the stock falls.
Rhea-AI Sentiment measures something else, the tone of the wording.
Hollow bars mark forward-looking points. How the balance works
Positive
- Major pointRoth agreement provides access to up to $50 million through optional common-stock sales; none have occurred. 13× market cap
- Moderate pointThird-quarter net loss narrowed to $3.547 million from $3.962 million; loss per common share fell to $0.18 from $0.34.
- Moderate pointThird-quarter research and development expenses declined to $1.832 million from $2.311 million a year earlier.
- Minor pointRatutrelvir median sustained symptom resolution was 13.5 days versus 14.5 days with PAXLOVID in eligible subjects.
- Minor pointTreatment-related adverse events affected 1 of 32 ratutrelvir patients versus 4 of 30 PAXLOVID patients.
9 minor points
- Minor pointRatutrelvir results showed no viral rebound through Day 28.
- Minor pointPAXLOVID-ineligible subjects had median symptom resolution of 14.0 days, with no treatment-related adverse events among 30 subjects.
- Minor point. Forward-looking: it has not happened yet and may not happen.Traws plans FDA discussions on a potential adaptive Phase 2b/pivotal program and Fast Track designation for PAXLOVID-ineligible patients.
- Minor pointTXM tablet bridging showed comparable exposure to the powder-in-capsule formulation and was well tolerated.
- Minor point. Forward-looking: it has not happened yet and may not happen.Traws believes TXM tablet results support further efficacy studies, including a planned human influenza challenge study.
- Minor pointTwo independent rat gene-mutation studies found no mutagenic effect up to 500 mg/kg, approximately 125-fold planned clinical exposure by dose.
- Minor point. Forward-looking: it has not happened yet and may not happen.Traws expects to resubmit TXM's updated toxicology package in fourth-quarter 2026.
- Minor pointNine-month other operating income was $1.405 million, versus none a year earlier.
- Minor pointTotal liabilities declined to $9.650 million at September 30, 2026, from $11.246 million at December 31, 2025.
Negative
- Major pointNine-month net results swung to a $14.864 million loss from $16.613 million income a year earlier.
- Major pointCommon shares outstanding increased to 15,375,595 at September 30, 2026, from 9,067,774 at December 31, 2025.
- Major point. Forward-looking: it has not happened yet and may not happen.Potential Roth sales involve new common stock, diluting existing holders if exercised.
- Moderate pointCash declined to $2.338 million at September 30, 2026, from $3.820 million at December 31, 2025.
- Moderate pointNine-month revenue fell to zero from $2.790 million a year earlier.
- Moderate pointNine-month research and development expenses increased to $9.037 million from $7.108 million a year earlier.
- Moderate pointCurrent liabilities of $9.642 million exceeded current assets of $4.977 million at September 30, 2026.
- Moderate pointStockholders' deficit widened to $2.128 million at September 30, 2026, from $629,000 at December 31, 2025.
4 minor points
- Minor pointNine-month basic common-share results fell to a $0.86 loss from $1.56 income; prior-year diluted income was $1.53.
- Minor pointNine-month administrative expenses rose to $7.283 million from $6.189 million; third-quarter expenses rose to $1.770 million from $1.744 million.
- Minor pointNine-month warrant-liability fair-value gains fell to $93,000 from $26.656 million a year earlier.
- Minor pointNine-month other results shifted to a $42,000 loss from $464,000 income; third-quarter income fell to $18,000 from $96,000.
Key Figures
- Study size
- 92 subjects
- Final ratutrelvir Phase 2a study
- Median time to symptom resolution
- 13.5 days with ratutrelvir vs. 14.5 days with PAXLOVID
- PAXLOVID-eligible subjects
- Treatment-related adverse events
- 1 of 32 ratutrelvir-treated patients vs. 4 of 30 PAXLOVID-treated patients
- PAXLOVID-eligible subjects
- Symptom resolution in PAXLOVID-ineligible subjects
- 14.0 days median; no treatment-related adverse events reported
- 30 subjects
- No-mutagenic-effect dose
- Up to 500 mg/kg
- Two independent rat Pig-a gene mutation studies; approximately 125-fold margin over planned clinical exposure based on dose
- Common stock purchase agreement
- Up to $50 million
- Traws has the right, but not the obligation, to sell common stock to Roth, subject to customary conditions
- Cash and cash equivalents
- $2.3 million vs. $3.8 million
- September 30, 2026 vs. December 31, 2025
- Net loss
- $3.5 million vs. $4.0 million
- Third quarter 2026 vs. third quarter 2025
Previous Earnings Reports
-
Reported a quarterly net loss and loss per share alongside program updates.
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Key Terms
phase 2a medical
common stock purchase agreement financial
mpro medical
cap-dependent endonuclease inhibitor medical
pig-a gene mutation studies technical
AI-generated analysis. How Rhea-AI works. Not financial advice.
- Ratutrelvir (COVID): Positive final Phase 2a results support further studies in PAXLOVID®-ineligible patients
- Tivoxavir marboxil (TXM, Influenza): Successful completion of tablet bridging study and toxicology retesting support a planned Q4 2026 regulatory resubmission
NEWTOWN, Pa., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Traws Pharma, Inc. (NASDAQ: TRAW, “Traws Pharma,” “Traws” or “the Company”), a clinical-stage biopharmaceutical company developing novel therapies for COVID-19 and influenza, today reported financial results for the quarter ended September 30, 2026, and provided business highlights for its two antiviral programs: ratutrelvir, a once-daily, ritonavir-free oral antiviral in development for COVID-19, and tivoxavir marboxil (TXM), an investigational long-acting agent for the prevention of seasonal and pandemic influenza.
“We have made meaningful progress toward our goal of developing new treatment and prevention options for patients most vulnerable to serious respiratory viral diseases,” said Iain Dukes, MA, DPhil, Chief Executive Officer of Traws Pharma. “For ratutrelvir, the final Phase 2a results support its potential as a once-daily, ritonavir-free treatment option for COVID-19, particularly for patients who are ineligible for PAXLOVID®. Our next priority is to engage the FDA on a registration strategy focused on these patients.”
“For tivoxavir marboxil, the tablet bridging study achieved its objectives, and toxicology retesting is complete. These results support further evaluation of TXM as a potential once-monthly oral influenza prevention option. We expect to resubmit the updated toxicology package in the fourth quarter,” concluded Dr. Dukes.
Recent Business Highlights
Ratutrelvir:
- Positive Phase 2a results Support Potential as a Ritonavir-Free Treatment Option. The final 92-subject study showed symptom resolution comparable to PAXLOVID®, with fewer treatment-related adverse events and no viral rebound through Day 28. Median time to sustained symptom resolution of 13.5 days with ratutrelvir versus 14.5 days with PAXLOVID® in eligible subjects. Treatment-related adverse events occurred in 1 of 32 ratutrelvir-treated patients versus 4 of 30 treated with PAXLOVID®. In 30 PAXLOVID®-ineligible subjects, median symptom resolution was 14.0 days, with no treatment-related adverse events reported.
- Regulatory Planning for PAXLOVID®-Ineligible Patients. Traws intends to discuss with the U.S. Food and Drug Administration (FDA) a registration strategy for adults at high risk of progression to severe COVID-19 who are ineligible for PAXLOVID®, including a potential adaptive Phase 2b/Pivotal program and Fast Track designation.
Tivoxavir Marboxil
- Promising New Compressed-Tablet Bridging Study Results. The compressed-tablet formulation provided exposure comparable to the powder-in-capsule formulation and was well tolerated. Consistent with the Company’s earlier modeling, the tablet could support once-monthly dosing. The Company believes the results also support TXM’s use in further efficacy studies, including a planned human influenza challenge study.
- TXM Toxicology Re-Testing Results Support Updated Regulatory Submissions. Two independent rat Pig-a gene mutation studies showed no mutagenic effect at doses up to 500 mg/kg, representing an approximately 125-fold margin over planned clinical exposure based on dose. Traws expects to resubmit the updated toxicology package to regulators in the fourth quarter of 2026.
Corporate Update
- Entered into a
$50 million common stock purchase agreement with Roth Principal Investments. Under the October 23, 2026 agreement, Traws has the right, but not the obligation, to sell up to$50 million of its common stock to Roth, subject to customary conditions. No shares have been sold under the agreement to date.
Third Quarter 2026 Financial Results
- Cash and cash equivalents.
$2.3 million as of September 30, 2026, compared with$3.8 million as of December 31, 2025. - Research and development expenses.
$1.8 million for the third quarter of 2026, compared with$2.3 million for the third quarter of 2025. - General and administrative expenses.
$1.8 million for the third quarter of 2026, compared with$1.7 million for the third quarter of 2025. - Net loss.
$3.5 million for the third quarter of 2026, compared with$4.0 million for the third quarter of 2025. Net loss per common share, basic and diluted, was$0.18 compared with$0.34 in the prior-year period. - Shares Outstanding: Traws had 15,368,277 shares of common stock outstanding as of November 13, 2026.
About Ratutrelvir
Ratutrelvir is an investigational oral, small molecule Mpro (3CL protease) inhibitor designed to act broadly against SARS-CoV-2/COVID-19 strains without the need for ritonavir. It has demonstrated in vitro activity against a range of virus strains. Industry data indicate that COVID treatment represents a potential multi-billion dollar market opportunity1. Ratutrelvir has not been approved by any regulatory authority.
About Tivoxavir Marboxil
Tivoxavir marboxil (TXM) is an investigational oral, small molecule CAP-dependent endonuclease inhibitor designed for single dose prevention of seasonal influenza and bird flu. It has shown in vitro activity against a range of influenza strains in preclinical studies. Seasonal influenza represents an estimated multi-billion-dollar antiviral market opportunity, largely driven by global health organizations, practice guidelines and government tenders and inclusion in drug stock piling initiatives2,3, with upside potential from potential pandemic flu outbreaks including H5N1 bird flu. TXM has not been approved by any regulatory authority.
About Traws Pharma, Inc.
Traws Pharma is a clinical-stage biopharmaceutical company dedicated to developing novel therapies to target critical threats to human health in respiratory viral diseases. Traws integrates antiviral drug development, medical intelligence and regulatory strategy to address real world challenges in the treatment of viral diseases. The Company is advancing novel investigational oral small molecule antiviral designed to have potent activity against difficult-to-treat or resistant virus strains. These include viruses associated with seasonal influenza and H5N1 bird flu, as well as negative-strand RNA viruses including Hantavirus, Ebola Virus Disease, and Lassa Fever and viruses associated with COVID-19/Long COVID.
Source Information
- Pfizer Inc. annual report on Form 10-K for the fiscal year ended December 31, 2025, filed with the U.S. Securities and Exchange Commission on February 3, 2026
- Per link
- Traws data on file
Third-party products mentioned herein are the trademarks of their respective owners. PAXLOVID® is a registered trademark of Pfizer Inc.
Forward-Looking Statements
Some of the statements in this release are forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995, and involve risks and uncertainties including statements regarding the Company, its business and product candidates, including the potential opportunity, market size, benefits, effectiveness, safety, and the clinical and regulatory plans for ratutrelvir and tivoxavir marboxil, as well as plans for its legacy programs. The Company has attempted to identify forward-looking statements by terminology including “believes”, “estimates”, “anticipates”, “expects”, “plans”, “intends”, “may”, “could”, “might”, “will”, “should”, “potential”, “preliminary”, “encouraging”, “approximately” or other words that convey uncertainty of future events or outcomes. Although Traws believes that the expectations reflected in such forward-looking statements are reasonable as of the date made, expectations may prove to have been materially different from the results expressed or implied by such forward looking statements. These statements are only predictions and involve known and unknown risks, uncertainties, and other factors, including planned discussions with the FDA, potential Fast Track designation, the outcome of Traws’ IND filing with the U.S. Food and Drug Administration (FDA) for tivoxavir marboxil, including the current FDA clinical hold; the success and timing of Traws’ clinical trials; the potential for tivoxavir marboxil or ratutrelvir to gain market acceptance, if and when regulatory approval is obtained, or to become the new standard of care; Traws’ interactions with the FDA, Biomedical Advanced Research and Development Authority (BARDA) and similar foreign regulators; collaborations; market conditions; regulatory requirements and pathways for approval; the extent of the spread and threat of the bird flu; COVID-19; seasonal flu; the Company’s cash projections; Traws’ ability to raise additional capital when needed; and those discussed under the heading “Risk Factors” in Traws’ filings with the U.S. Securities and Exchange Commission (SEC). Any forward-looking statements contained in this release speak only as of its date. Traws undertakes no obligation to update any forward-looking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events, except to the extent required by law.
Contacts
Traws Pharma Contact:
Charles Parker
Traws Pharma, Inc.
cparker@trawspharma.com
www.trawspharma.com
Investor Contact:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
| Traws Pharma, Inc. Condensed Consolidated Statements of Operations (unaudited) | |||||||||||||||
| Three Months Ended September 30, | Nine Months Ended September 30, | ||||||||||||||
| 2026 | 2025 | 2026 | 2025 | ||||||||||||
| Revenue | $ | — | $ | — | $ | — | $ | 2,790,000 | |||||||
| Operating expenses (income): | |||||||||||||||
| Research and development | 1,832,000 | 2,311,000 | 9,037,000 | 7,108,000 | |||||||||||
| General and administrative | 1,770,000 | 1,744,000 | 7,283,000 | 6,189,000 | |||||||||||
| Other operating income | — | — | (1,405,000 | ) | — | ||||||||||
| Total operating expenses, net | 3,602,000 | 4,055,000 | 14,915,000 | 13,297,000 | |||||||||||
| Loss from operations | (3,602,000 | ) | (4,055,000 | ) | (14,915,000 | ) | (10,507,000 | ) | |||||||
| Change in fair value of warrant liability | 37,000 | (3,000 | ) | 93,000 | 26,656,000 | ||||||||||
| Other income (loss), net | 18,000 | 96,000 | (42,000 | ) | 464,000 | ||||||||||
| Net (loss) income | $ | (3,547,000 | ) | $ | (3,962,000 | ) | $ | (14,864,000 | ) | $ | 16,613,000 | ||||
| Net (loss) income attributable to common stockholders, basic and diluted | $ | (3,063,000 | ) | $ | (3,035,000 | ) | $ | (12,540,000 | ) | $ | 12,263,000 | ||||
| Weighted-average shares of common stock outstanding, basic | 17,044,826 | 8,818,859 | 14,539,956 | 7,851,515 | |||||||||||
| Net (loss) income per share of common stock, basic | $ | (0.18 | ) | $ | (0.34 | ) | $ | (0.86 | ) | $ | 1.56 | ||||
| Weighted-average shares of common stock outstanding, diluted | 17,044,826 | 8,818,859 | 14,539,956 | 8,006,487 | |||||||||||
| Net (loss) income per share of common stock, diluted | $ | (0.18 | ) | $ | (0.34 | ) | $ | (0.86 | ) | $ | 1.53 | ||||
| Net (loss) income attributable to Series C Preferred stockholders, basic and diluted | $ | (484,000 | ) | $ | (927,000 | ) | $ | (2,324,000 | ) | $ | 4,350,000 | ||||
| Weighted-average shares of Series C Preferred outstanding, basic and diluted | 6,737 | 6,737 | 6,737 | 6,962 | |||||||||||
| Net (loss) income per share of Series C Preferred, basic and diluted | $ | (71.84 | ) | $ | (137.60 | ) | $ | (344.96 | ) | $ | 624.82 | ||||
| Traws Pharma, Inc. Condensed Consolidated Balance Sheets (unaudited) | |||||||
| September 30, | December 31, | ||||||
| 2026 | 2025 | ||||||
| Assets | |||||||
| Current assets: | |||||||
| Cash and cash equivalents | $ | 2,338,000 | $ | 3,820,000 | |||
| Tax incentive and other receivables | 2,195,000 | 3,794,000 | |||||
| Prepaid expenses and other assets | 444,000 | 365,000 | |||||
| Total current assets | 4,977,000 | 7,979,000 | |||||
| Property and equipment, net | 5,000 | 7,000 | |||||
| Intangible assets, net | 2,398,000 | 2,527,000 | |||||
| Other assets | 142,000 | 104,000 | |||||
| Total assets | $ | 7,522,000 | $ | 10,617,000 | |||
| Liabilities and stockholders’ deficit | |||||||
| Current liabilities: | |||||||
| Accounts payable | $ | 6,651,000 | $ | 5,653,000 | |||
| Accrued expenses and other liabilities | 2,991,000 | 5,493,000 | |||||
| Total current liabilities | 9,642,000 | 11,146,000 | |||||
| Warrant liabilities | 8,000 | 100,000 | |||||
| Total liabilities | 9,650,000 | 11,246,000 | |||||
| Commitments and contingencies (Note 5) | |||||||
| Stockholders’ deficit: | |||||||
| Series C Preferred stock, | — | — | |||||
| Common stock, | 153,000 | 90,000 | |||||
| Additional paid-in capital | 652,574,000 | 639,259,000 | |||||
| Accumulated deficit | (654,848,000 | ) | (639,984,000 | ) | |||
| Accumulated other comprehensive (loss) income | (7,000 | ) | 6,000 | ||||
| Total stockholders’ deficit | (2,128,000 | ) | (629,000 | ) | |||
| Total liabilities and stockholders’ deficit | $ | 7,522,000 | $ | 10,617,000 | |||
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.
What were Traws Pharma's third-quarter 2026 financial results?
Traws reported a $3.547 million net loss, compared with $3.962 million a year earlier. Basic and diluted loss per common share was $0.18 versus $0.34. Cash and cash equivalents totaled $2.338 million at September 30, 2026.
What did Traws Pharma's ratutrelvir Phase 2a trial show?
The final 92-subject study showed median sustained symptom resolution of 13.5 days with ratutrelvir versus 14.5 days with PAXLOVID in eligible subjects. Treatment-related adverse events occurred in 1 of 32 ratutrelvir patients versus 4 of 30 PAXLOVID patients. Results showed no viral rebound through Day 28.
Could Traws Pharma's TXM tablet support monthly influenza prevention?
Traws believes the TXM tablet could support once-monthly dosing, consistent with its earlier modeling. The bridging study found exposure comparable to the powder-in-capsule formulation, and the tablet was well tolerated. Monthly prevention remains a potential use rather than an established outcome.